pre-IPO PHARMA

artizan-biosciences PRESS RELEASE ARCHIVE

Jul 21, 2022

Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL


Mar 29, 2022

Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform


Jan 18, 2022

Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program


Nov 18, 2021

Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease


Oct 19, 2021

Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer



Oct 19, 2021

Artizan Biosciences Announces Appointment of Dr. Bridget Martell as President and Chief Executive Officer


Mar 1, 2021

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics


Feb 25, 2020

Trianni, Inc. Announces License Agreement with Artizan Biosciences, Inc. for the Trianni Mouse


Jun 10, 2019

Artizan Biosciences Announces Corporate Progress and Financing


Feb 6, 2017

Malin Makes Significant Commitment to Artizan Biosciences, Inc.



Google Analytics Alternative